Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Chronic Graft Versus Host Disease: early-phase trial registry
15 of 31 indexed Chronic Graft Versus Host Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #495 of 28,707 conditions by registered trial count.
31 US clinical trials · 15 currently recruiting · #495 of 28,707 conditions by registered trial count
Chronic Graft Versus Host Disease: 31 US clinical trials tracked, 15 recruiting.
Chronic Graft Versus Host Disease is the subject of 31 registered US clinical trials on ClinicalTrials.gov, 15 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most active sponsor is Fred Hutchinson Cancer Center, running 5 of these trials.
Enrollment posture brief
Registry condition chronic-graft-versus-host-disease
OPEN 15 | RECR 48% | LATE 4 | EARLY 19 | RANK #495 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Genetic Disease (48% recruiting · 31 trials)
Chronic Graft Versus Host Disease lists 15 open slots (48% of 31 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Chronic Graft Versus Host Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Chronic Graft Versus Host Disease is recruiting above its size-band peers.
15 of 31 indexed trials (48.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Chronic Graft Versus Host Disease research.
Fred Hutchinson Cancer Center accounts for 5 of 31 trials (16.1%). 17 distinct sponsors appear on at least one study for this condition label.
-
Most Chronic Graft Versus Host Disease trials plan to enrol fewer than 100 people.
Median target enrolment is 40 among the 31 trials that report a genuine target (sentinel values excluded). 22 of those (71%) plan for fewer than 100 participants.
-
Chronic Graft Versus Host Disease research is mostly interventional.
27 interventional and 4 observational studies make up this index (87.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
31 total, page 1 of 1
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Janssen Research & Development
NCT01804686
Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study
Fred Hutchinson Cancer Center
NCT04431479
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Incyte Corporation
NCT06585774
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
Incyte Corporation
NCT06388564
Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease
Fred Hutchinson Cancer Center
NCT05996627
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
Incyte Corporation
NCT07124078
Axatilimab for Sclerotic Chronic Graft-versus-Host Disease
Fred Hutchinson Cancer Center
NCT07011810
Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease
University of Miami
NCT06663722
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
Dana-Farber Cancer Institute
NCT05922761
Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
Mayo Clinic
NCT06271616
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
Sanofi
NCT07116031
Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial
Dana-Farber Cancer Institute
NCT05236062
Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD
Stefanie Sarantopoulos, MD, PhD.
NCT06233110
Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease
Northside Hospital
NCT06046248
Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD
M.D. Anderson Cancer Center
NCT07127926
Improving Outcomes Assessment in Chronic GVHD
Fred Hutchinson Cancer Center
NCT00637689
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
Sanofi
NCT06143891
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
Syndax Pharmaceuticals
NCT04710576
Psychosocial Mobile App for Chronic Graft-Versus-Host Disease
Massachusetts General Hospital
NCT05690971
Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
Dana-Farber Cancer Institute
NCT01366092
Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
Dana-Farber Cancer Institute
NCT01937468
Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease
Washington University School of Medicine
NCT02611180
Digital Health Intervention to Promote Quality of Life in Adults With Chronic Graft Versus Host Disease
University of Miami
NCT06688942
A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib
Incyte Corporation
NCT04640025
Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease
City of Hope Medical Center
NCT04212416
Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation
National Cancer Institute (NCI)
NCT02669251
Tele-Palliative Care Intervention for Patients With Chronic Graft-Versus-Host Disease
Massachusetts General Hospital
NCT06458127
Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)
Pharmacyclics
NCT02959944
Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease
H. Lee Moffitt Cancer Center and Research Institute
NCT01680965
Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
National Cancer Institute (NCI)
NCT02759731
Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease
Fred Hutchinson Cancer Center
NCT02491359
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 13 |
| Phase 3 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Chronic Graft Versus Host Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Chronic Graft Versus Host Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Chronic Graft Versus Host Disease page
31 registered trials, 15 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 15 Chronic Graft Versus Host Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Fred Hutchinson Cancer Center sponsors the most Chronic Graft Versus Host Disease trials on record, review their full trial history before evaluating a specific study. See Fred Hutchinson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chronic Graft Versus Host Disease condition card totals 31 registered trials; most-linked intervention Belumosudil; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.